FibroBiologics (FBLG) Interest Expenses (2022 - 2026)
FibroBiologics (FBLG) posted quarterly Interest Expenses of $1.5 million for Q2 2026, down 50.5% year-over-year from $3.1 million in Q2 2025, and down 38.57% on a QoQ basis from $2.5 million in Q1 2026.
FibroBiologics (FBLG) Interest Expenses (2022 - 2026) Analysis & Trends
FibroBiologics has reported Interest Expenses for 5 years, with the latest figure at $1.5 million in Q2 2026.
- Interest Expenses for Q2 2026 came in at $1.5 million, down 50.5% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.5 million (down 50.5% YoY), and the FY2025 annual result was $9.2 million, up 75.58% from the prior year.
- Interest Expenses slipped to $1.5 million in Q2 2026, from $2.5 million in the prior quarter.
- Over five years, Interest Expenses peaked at $3.1 million in Q2 2025 and troughed at -$145000.0 in Q3 2023.
- A 5-year average of $1.1 million and a median of $199000.0 in 2025 frame the typical range for Interest Expenses.
- The widest annual swing landed in 2024, when Interest Expenses plunged 97.04%; it then soared 62200.0% in 2025.
- A 5-year view of Interest Expenses shows it stood at $1.3 million in 2022, then slumped by 88.47% to $146000.0 in 2023, then sank by 95.89% to $6000.0 in 2024, then jumped by 3216.67% to $199000.0 in 2025, then surged by 674.87% to $1.5 million in 2026.
- Per Business Quant data, the three most recent Interest Expenses figures were $1.5 million in Q2 2026, $2.5 million in Q1 2026, and $199000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | FibroBiologics | 8.97 Mn | 8.97 Mn | - | 7,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.54 Mn |
| Jun 30, 2026 | 1.54 Mn |
| Mar 31, 2026 | 2.51 Mn |
| Mar 31, 2026 | 2.51 Mn |
| Dec 31, 2025 | 199,000.00 |
| Dec 31, 2025 | 199,000.00 |
| Sep 30, 2025 | 2.90 Mn |
| Sep 30, 2025 | 2.90 Mn |
| Jun 30, 2025 | 576,000.00 |
| Jun 30, 2025 | 576,000.00 |
| Mar 31, 2025 | 1.41 Mn |
| Mar 31, 2025 | 1.41 Mn |
| Dec 31, 2024 | 6,000.00 |
| Dec 31, 2024 | 6,000.00 |
| Sep 30, 2024 | 3.02 Mn |
| Sep 30, 2024 | 3.02 Mn |
| Jun 30, 2024 | 5,000.00 |
| Jun 30, 2024 | 5,000.00 |
| Mar 31, 2024 | 4,000.00 |
| Mar 31, 2024 | 4,000.00 |